Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorInsel Gruppe AG, University Hospital Bern
About this trial
Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification.
The investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS.
The primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.
Eligibility criteria
Qualifiers
Age
≥ 65 years
NT-proBNP >400 pg/mL
Left atrial ventricular index >42 ml/m2 or left atrial diameter >46 mm
Disqualifiers
History of AF or atrial flutter
Patients with a history of symptoms compatible with an AIS, covert neurological deficits are allowed.
Cardiac implantable electronic devices (pacemaker, implantable cardiac defibrillator (ICD), implantable cardiac monitor (ICM))
Indication for cardiac implantable electronic device implantation (pacemaker, ICD, ICM)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov